Clinical Data Boehringer advances duo for aggressive cancers into phase 3 PharmaphorumBoehringer Ingelheim steps up its push into oncology with phase 3 trials for pathfinder product Hernexeos and obrixtamig in hard-to-treat cancers.OncologyRead full story pharminent June 22, 2026 (Last updated: June 22, 2026) Pharmaphorum Boehringer Ingelheim steps up its push into oncology with phase 3 trials for pathfinder product Hernexeos and obrixtamig in hard-to-treat cancers. Oncology Read full story Post navigation Previous: Insilico and SK Bio forge $2.5bn AI neuroimmunity allianceNext: Lilly bets up to $800M for BioArctic’s brain delivery tech Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026